JP6774435B2 - 抗ウイルス活性を有する鼻づまり解除組成物 - Google Patents

抗ウイルス活性を有する鼻づまり解除組成物 Download PDF

Info

Publication number
JP6774435B2
JP6774435B2 JP2017565990A JP2017565990A JP6774435B2 JP 6774435 B2 JP6774435 B2 JP 6774435B2 JP 2017565990 A JP2017565990 A JP 2017565990A JP 2017565990 A JP2017565990 A JP 2017565990A JP 6774435 B2 JP6774435 B2 JP 6774435B2
Authority
JP
Japan
Prior art keywords
aqueous solution
carrageenan
solution according
nasal
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017565990A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523635A (ja
JP2018523635A5 (cg-RX-API-DMAC7.html
Inventor
グラッサウアー,アンドレアス
プリィシゥル‐グラッサウアー,エバ
ボーデンタイヒ,アンジェリカ
コーラー,クリスチャーヌ
モロクッティ‐クルツ,マーティーナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marinomed Biotech AG
Original Assignee
Marinomed Biotechnologie GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marinomed Biotechnologie GmbH filed Critical Marinomed Biotechnologie GmbH
Publication of JP2018523635A publication Critical patent/JP2018523635A/ja
Publication of JP2018523635A5 publication Critical patent/JP2018523635A5/ja
Application granted granted Critical
Publication of JP6774435B2 publication Critical patent/JP6774435B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731Carrageenans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2017565990A 2015-07-14 2016-07-12 抗ウイルス活性を有する鼻づまり解除組成物 Active JP6774435B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15176670 2015-07-14
EP15176670.6 2015-07-14
PCT/EP2016/066565 WO2017009351A1 (en) 2015-07-14 2016-07-12 Stuffy nose deblocking composition having antiviral activity

Publications (3)

Publication Number Publication Date
JP2018523635A JP2018523635A (ja) 2018-08-23
JP2018523635A5 JP2018523635A5 (cg-RX-API-DMAC7.html) 2019-07-18
JP6774435B2 true JP6774435B2 (ja) 2020-10-21

Family

ID=53717900

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017565990A Active JP6774435B2 (ja) 2015-07-14 2016-07-12 抗ウイルス活性を有する鼻づまり解除組成物

Country Status (26)

Country Link
US (1) US10660914B2 (cg-RX-API-DMAC7.html)
EP (1) EP3370692B1 (cg-RX-API-DMAC7.html)
JP (1) JP6774435B2 (cg-RX-API-DMAC7.html)
KR (1) KR102628781B1 (cg-RX-API-DMAC7.html)
CN (1) CN107847430B (cg-RX-API-DMAC7.html)
AU (1) AU2016293004B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018000592B1 (cg-RX-API-DMAC7.html)
CA (1) CA2992352C (cg-RX-API-DMAC7.html)
CL (1) CL2018000033A1 (cg-RX-API-DMAC7.html)
DK (1) DK3370692T3 (cg-RX-API-DMAC7.html)
EA (1) EA037085B1 (cg-RX-API-DMAC7.html)
ES (1) ES2949139T3 (cg-RX-API-DMAC7.html)
FI (1) FI3370692T3 (cg-RX-API-DMAC7.html)
HU (1) HUE062108T2 (cg-RX-API-DMAC7.html)
IL (1) IL256883B (cg-RX-API-DMAC7.html)
LT (1) LT3370692T (cg-RX-API-DMAC7.html)
MA (1) MA43155A (cg-RX-API-DMAC7.html)
MX (1) MX372625B (cg-RX-API-DMAC7.html)
MY (1) MY194870A (cg-RX-API-DMAC7.html)
NZ (1) NZ738597A (cg-RX-API-DMAC7.html)
PH (1) PH12018500044B1 (cg-RX-API-DMAC7.html)
PL (1) PL3370692T3 (cg-RX-API-DMAC7.html)
PT (1) PT3370692T (cg-RX-API-DMAC7.html)
SA (1) SA518390689B1 (cg-RX-API-DMAC7.html)
WO (1) WO2017009351A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201708595B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017220396B2 (en) * 2016-02-17 2022-12-15 Ent Technologies Pty Ltd Compositions and methods for the treatment of sinus disease and disorders
GB2567285A (en) * 2017-08-07 2019-04-10 Suprapharm Cc Preparation for nasal-nasopharyngeal treatment
PH12022552298A1 (en) 2020-03-12 2023-12-11 Cullis Hill Sydney David Treatment for coronavirus infection and associated cytokine toxicity
CN111437270A (zh) * 2020-04-24 2020-07-24 瑞希(重庆)生物科技有限公司 一种卡拉胶鼻用即型凝胶喷雾剂及其制备方法
US11013687B1 (en) * 2020-06-08 2021-05-25 Amcyte Pharma, Inc. Preventive and therapeutic treatment for COVID 19 and any other disease caused by SARS CoV 2
WO2021253643A1 (zh) * 2020-06-18 2021-12-23 大连工业大学 硫酸化多糖在抗新型冠状病毒中的应用
CN111686125A (zh) * 2020-06-18 2020-09-22 大连工业大学 卡拉胶在抗新型冠状病毒中的应用
BR112022026026A2 (pt) * 2020-06-22 2023-03-07 Elmen Tremblay Mario Lubrificantes pessoais compreendendo lambda-carragenina
EP3939597A1 (en) * 2020-07-16 2022-01-19 Marinomed Biotech AG Antiviral pharmaceutical composition comprising a carrageenan component
US20230330013A1 (en) * 2020-08-04 2023-10-19 Cosmosoft Hydrogel comprising glycerol and a carbomer for treating the respiratory symptoms of covid-19 disease via the nasal route
FR3113237B1 (fr) 2020-08-04 2023-06-09 Biopass Produit pour le traitement de maladies virales par voie nasale
DE202020004186U1 (de) * 2020-10-05 2020-10-21 Christian Fleischhammel Antiinfektive Arzneiform zur Herstellung einer Nasenspülung gegen COVID-19
EP3991561A1 (en) * 2020-10-28 2022-05-04 Vepidan ApS Antimicrobial disinfectant gel
GB202109888D0 (en) 2021-07-08 2021-08-25 Pollinner Ltd Nasal spray
KR102720037B1 (ko) * 2021-12-21 2024-10-22 (주)메디코어 비강 세정제 조성물 및 그 제조방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2653021A1 (fr) * 1989-10-17 1991-04-19 Merck Sharp & Dohme Composition ophtalmique aqueuse liquide a transition de phase liquide-gel.
US6080783A (en) * 1998-09-01 2000-06-27 Gum Tech International, Inc. Method and composition for delivering zinc to the nasal membrane
NZ555501A (en) * 2004-11-24 2010-01-29 Medpointe Healthcare Inc Compositions comprising azelastine and methods of use thereof
US20080241271A1 (en) * 2006-11-08 2008-10-02 Roman Stephen B Foaming anti-adhesion composition
PL2101792T3 (pl) 2006-12-05 2010-11-30 Marinomed Biotechnologie Gmbh Zastosowanie karageniny do leczenia zakażeń rinowirusem
JP4941977B2 (ja) * 2007-04-11 2012-05-30 大蔵製薬株式会社 ベンズイソキサゾール誘導体の経口ゼリー状医薬組成物
CA2696009C (en) 2007-08-24 2016-08-02 Marinomed Biotechnologie Gmbh Antiviral composition comprising a sulfated polysaccharide
JP5634066B2 (ja) * 2007-11-06 2014-12-03 三栄源エフ・エフ・アイ株式会社 唾液分泌促進剤
FR2926218B1 (fr) 2008-01-10 2010-08-13 Galderma Res & Dev Composition comprenant un retinoide et du peroxyde de benzoyle disperse.
WO2013049538A1 (en) * 2011-09-30 2013-04-04 Mcneil-Ppc, Inc. Allergen nasal compositions

Also Published As

Publication number Publication date
JP2018523635A (ja) 2018-08-23
CA2992352C (en) 2023-06-27
EA037085B1 (ru) 2021-02-04
EP3370692A1 (en) 2018-09-12
AU2016293004B2 (en) 2021-05-06
MA43155A (fr) 2018-09-12
PH12018500044B1 (en) 2022-04-27
NZ738597A (en) 2021-12-24
IL256883A (en) 2018-03-29
FI3370692T3 (fi) 2023-06-16
CN107847430A (zh) 2018-03-27
CN107847430B (zh) 2021-02-02
LT3370692T (lt) 2023-07-10
PH12018500044A1 (en) 2018-07-23
SA518390689B1 (ar) 2021-07-17
PT3370692T (pt) 2023-07-18
PL3370692T3 (pl) 2023-08-14
EA201890196A1 (ru) 2018-06-29
MX2018000285A (es) 2018-02-19
KR20180054570A (ko) 2018-05-24
DK3370692T3 (da) 2023-06-26
MX372625B (es) 2020-05-12
HK1253038A1 (zh) 2019-06-06
KR102628781B1 (ko) 2024-01-24
US20190060358A1 (en) 2019-02-28
ES2949139T3 (es) 2023-09-25
ZA201708595B (en) 2021-06-30
IL256883B (en) 2021-07-29
CL2018000033A1 (es) 2018-08-10
BR112018000592B1 (pt) 2024-02-06
BR112018000592A2 (pt) 2018-09-11
US10660914B2 (en) 2020-05-26
WO2017009351A1 (en) 2017-01-19
EP3370692B1 (en) 2023-04-12
CA2992352A1 (en) 2017-01-19
AU2016293004A1 (en) 2018-01-18
MY194870A (en) 2022-12-21
HUE062108T2 (hu) 2023-09-28

Similar Documents

Publication Publication Date Title
JP6774435B2 (ja) 抗ウイルス活性を有する鼻づまり解除組成物
US8901172B2 (en) Method for treating an inflammation or lesion caused by a virus
US20090191288A1 (en) Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases
ES2834985T3 (es) Composición que contiene cineol para administración nasal
RS49721B (sr) Kompozicija koja sadrži biljku i površinski aktivno sredstvo korisna u proizvodnji proizvoda za tretiranje herpesa i drugih mikrobnih infekcija
BR122014006936B1 (pt) Composiçao farmaceutica compreendendo na forma de um anel intravaginal
US9662360B2 (en) Treatment of herpes, pseudomonas, staph, and hepatitis
EP1372389B1 (en) Virucidal compositions
WO2021184070A1 (en) Antiviral composition for oral care
ES2860098T3 (es) Composición para la aplicación nasal
US20230355668A1 (en) Hydroxyapatite composition for treatment and/or prevention of a virus infection
US20170274083A1 (en) Nasal composition having anti-viral properties
CN114288307B (zh) 一种含唾液酸盐的产品及其应用
HK1253038B (zh) 一种具有抗病毒活性的鼻塞疏通组合物
EP2985027B1 (en) Nasal composition comprising mixture of hyaluronic acids and saline solution
SA90110074B1 (ar) تركيبات صيدلانية متضمنة على محلول مائي من مشتق بيرانوكوينولين pyranoquinoline
RU2780109C1 (ru) Противовоспалительные глазные капли для домашних и сельскохозяйственных животных
US20240148838A1 (en) Composition for Treatment and/or Prevention of a Corona Virus Infection
PL220390B1 (pl) Profilaktyczno higieniczny środek do płukania i nawilżania nosa

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200812

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200929

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201002

R150 Certificate of patent or registration of utility model

Ref document number: 6774435

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250